CXCR7 Antagonists
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application 61/731,463, filed Nov 29, 2012. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,169,261 | CXCR7 Antagonists In force · High confidence | Chemocentryx, Inc. | In force | High confidence | ||
| US 9,783,544 | CXCR7 Antagonists In force · High confidence | Chemocentryx, Inc. | In force | High confidence | ||
| US 10,287,292 | CXCR7 Antagonists In force · High confidence | Chemocentryx, Inc. | In force | High confidence | ||
| US 11,059,825 | CXCR7 Antagonists In force · High confidence | Chemocentryx, Inc. | In force | High confidence | ||
| US 11,834,452 | CXCR7 Antagonists In force · High confidence | Chemocentryx, Inc. | In force | High confidence |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.